Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report.

This article discusses a case report of a pharmacokinetic drug-drug interaction between olaparib and apixaban in a cancer patient. The patient was receiving off-label treatment with olaparib and also taking apixaban for the prevention of deep vein thrombosis recurrence. The study found that the concurrent use of olaparib and apixaban resulted in a 2.1-fold increase in apixaban concentration. This interaction could potentially increase the risk of bleeding in patients. The authors recommend a multidisciplinary approach and therapeutic drug monitoring for cancer patients receiving both apixaban and olaparib. [Extracted from the article]